Minger has joined GE Healthcare Life Sciences as head of R&D for cell technologies...For its part, GE Healthcare's current focus in stem cells is in providing enabling technologies for their use in drug discovery and autologous cell therapies

The most recent in June was of GE Healthcare's custom radiolabeling business, based in Cardiff, UK

Total: $6,230.1M Company Location Date Amt. (M) Details JANUARY 4-Antibody AG Basel, Switzerland 1/16/07 CHF17 (US$13.6) 4-Antibody raised CHF17M in its Series A round led by Advent Venture Partners; other investors were Biomedinvest AG, Grazia Equity GmbH, Life Sciences Partners and Mulligan Biocapital AG, as well as several private investors Althea Technologies Inc. San Diego 1/9/07 $23 Investing in the Series C financing investment were funds managed by Telegraph Hill Partners

financial details were not disclosed (6/24) Geron Corp. (GERN) GE Healthcare (UK; unit of General Electric Co.) Global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening Financial terms were not disclosed (6/30) Merck & Co

Geron Corp., of Menlo Park, Calif., and GE Healthcare, of Chalfont St. Giles, UK, a unit of the General Electric Co., said they entered a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening

for each combination advanced to the market from the collaboration, CombinatoRx is eligible to receive up to $58M in milestones (5/6) Cytori Therapeutics Inc. (CYTX) GE Healthcare (UK; unit of General Electric Co.) An 18-month agreement for GE to commercialize Cytori's StemSource technology in the North American stem cell banking and research markets StemSource includes automated equipment to process stem and regenerative cells found in adipose tissue for cryopreservation or use in research

Peters most recently served as president and CEO of the medical diagnostics business at GE Healthcare

Cytori Therapeutics Inc., of San Diego, and Chalfont St. Giles, UK-based GE Healthcare, a unit of General Electric Co., entered an 18-month agreement for GE to commercialize Cytori's StemSource technology in the North American stem cell banking and research markets

HUNT Biosciences, of Levanger, Norway, appointed Per Foss, formerly GE Healthcare director, as CEO

HUNT Biosciences, of Levanger, Norway, appointed Per Foss, formerly GE Healthcare director, as CEO

the agreement is an extension of an existing license in the Middle East and Africa (3/5) Novozymes Biopharma UK Ltd. (UK; LSE:NVZ) GE Healthcare Life SciencesLicense agreement that enables Novozymes to produce and deliver native, animal-free protein A using GE technology Terms were not disclosed (3/9) Targeted Genetics Corp. (TGEN) Celladon Corp.* License and manufacturing agreements to enable Celladon to manufacture Mydicar through commercial manufacturing organizations or a

Second, that GE Healthcare is the source of the equipment used to extract the fat tissue used in the procedure

Novozymes Bioalliance UK Ltd., of Nottingham, UK, said it signed a license agreement with GE Healthcare Life Sciences, of Piscataway, N.J., enabling Novozymes to produce and deliver native, animal-free protein A using GE technology

Novozymes Biopharma UK Ltd., of Nottingham, UK, said it signed a license agreement with GE Healthcare Life Sciences, of Piscataway, N.J., enabling Novozymes to produce and deliver native, animal-free protein A using GE technology

Agreement to supply bulk adenovirus for the manufacture of adenovirus types 4 and 7 live oral vaccines Further terms were not disclosed (1/6) Cytori Therapeutics Inc. (CYTX) GE Healthcare Partnership to commercialize Cytori's Celution System in select European countries GE Healthcare will commercialize the Celution System in the areas of cosmetic and reconstructive surgery, translational medicine and stem cell banking in combination with Cytori's StemSource Cell Bank product (1/12) Rosetta

the total deal is worth up to $203.3M (1/13) AuricX Pharmaceuticals* SRI International Agreement to gain rights to oral formulations of vancomycin SRI received an undisclosed up-front payment and will be eligible for success-based milestones and royalties on sales (1/12) Beatica AB* (Sweden) GE Healthcare Research collaboration to develop the next generation of Biacore surface plasmon resonance instruments and applications for fragment-based drug discovery Financial terms were not

January | February | March | April | May | June | July | August | September | October | November | December | December - 2009 Biotech Company Pharma Company Type/Product Area Terms/Details Adimab Inc. Pfizer Inc.; an undisclosed company Agreement for Adimab to deliver fully human antibodies against a central nervous system target selected by Pfizer; the new deal with the undisclosed company will focus on an oncology target Both deals involve up-front fees, milestone payments

January | February | March | April | May | June | July | August | September | October | November | December | December - 2009 Company Company Type/Product Area Terms/Details Alkermes Inc. (ALKS) Acceleron Pharma Inc. Licensing agreement for a long-acting Fc fusion technology platform Alkermes gains worldwide rights to Medifusion in return for an up-front payment and equity investment in Acceleron, plus future milestones and royalties Allos Therapeutics Inc. (ALTH) Idis

Beactica AB, of Uppsala, Sweden, entered a new research collaboration agreement with GE Healthcare, of Chalfont St. Giles, UK, and Uppsala University to develop the next generation of Biacore surface plasmon resonance instruments and applications for fragment-based drug discovery